ArticleMedicina (Kaunas, Lithuania)2025

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy.

Rumeysa Colak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.